Document Detail


Primary aldosteronism - treatment options.
MedLine Citation:
PMID:  12914736     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Diagnosis of primary aldosteronism results in either the surgical cure of hypertension or targeted pharmacotherapy. The two major subtypes of primary aldosteronism are unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA). Patients with APA usually are treated with unilateral adrenalectomy and patients with IHA are treated medically. The majority of patients with primary aldosteronism have the IHA subtype and require pharmacotherapy. Spironolactone has been the drug of choice to treat primary aldosteronism. However, it is not selective for the aldosterone receptor, and side effects include gynecomastia, erectile dysfunction and menstrual irregularity. Eplerenone is a new competitive and selective aldosterone receptor antagonist recently approved by the United States Food and Drug Administration for the treatment of hypertension. It lacks the side effects associated with spironolactone and will be the superior drug if it is shown to be as effective as spironolactone for the treatment of mineralocorticoid-dependent hypertension.
Authors:
William F Young
Related Documents :
22473646 - Comparative transcutaneous immunization with imiquimod containing ointments and potenti...
8417406 - Pharmacologic management of childhood hypertension.
22791836 - Dependence and psychosis with 4-methylmethcathinone (mephedrone) use.
22707046 - Real-time assessment of ultrasound-mediated drug delivery using fibered confocal fluore...
8268386 - Chitosan matrix for oral sustained delivery of ampicillin.
23152886 - Quercetin suppresses drug-resistant spheres via the p38 mapk-hsp27 apoptotic pathway in...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society     Volume:  13 Suppl A     ISSN:  1096-6374     ISO Abbreviation:  Growth Horm. IGF Res.     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-08-13     Completed Date:  2004-05-13     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  9814320     Medline TA:  Growth Horm IGF Res     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  S102-8     Citation Subset:  IM    
Affiliation:
Divisions of Endocrinology, Metabolism, Nutrition and Internal Medicine, Mayo Medical School, Mayo Clinic and Mayo Foundation, 200 First Street S.W., Rochester, MN 55905, USA. young.william@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Hyperaldosteronism / complications,  diagnosis,  therapy*
Hypertension / diagnosis,  etiology,  therapy
Hypokalemia / diagnosis,  etiology,  therapy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  End-stage renal disease: endocrine aspects of treatment.
Next Document:  Growth hormone and cardiovascular risk markers.